Prescription and Other Medication Use in Pregnancy by Haas, David M. et al.
Prescription and Other Medication Use in Pregnancy
David M. Haas, MD, MS1, Derek J. Marsh, MS2, Danny T. Dang, MD1, Corette B. Parker, 
DrPH2, Deborah A. Wing, MD, MBA3, Hyagriv N. Simhan, MD4, William A. Grobman, MD, 
MBA5, Brian M. Mercer, MD6, Robert M. Silver, MD7, Matthew K. Hoffman, MD8, Samuel 
Parry, MD9, Jay D. Iams, MD10, Steve N. Caritis, MD4, Ronald J. Wapner, MD11, M. Sean 
Esplin, MD7, Michal A. Elovitz, MD9, Alan M. Peaceman, MD5, Judith Chung, MD3, George 
R. Saade, MD12, Uma M. Reddy, MD, MPH13, and for the Nulliparous Pregnancy Outcomes 
Study: Monitoring Mothers-to-be (nuMoM2b) study
1Indiana University, Galveston, TX
2RTI International, Galveston, TX
3University of California- Irvine, Galveston, TX
4University of Pittsburgh, Galveston, TX
5Northwestern University, Galveston, TX
6Case Western Reserve University, Galveston, TX
7University of Utah, Galveston, TX
8Christiana Care, Galveston, TX
9University of Pennsylvania, Galveston, TX
10Ohio State University, Galveston, TX
11Columbia University, Galveston, TX
12University of Texas Medical Branch, Galveston, TX
13Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Abstract
Objective—To characterize prescription and other medication use in a geographically and 
ethnically diverse cohort of women in their first pregnancy.
Methods—In a prospective, longitudinal cohort study, nulliparous women followed through 
pregnancy from the first trimester, medication use was chronicled longitudinally throughout 
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pregnancy. Structured questions and aids were utilized to capture all medications taken as well as 
reasons they were taken. Total counts of all medications taken including number in each category 
and class were captured. Additionally, reasons the medications were taken were recorded. Trends 
in medications taken across pregnancy and in the first trimester were determined.
Results—Of the 9,546 study participants, 9,272 (97.1%) women took at least one medication 
during pregnancy, with 9,139 (95.7%) taking a medication in the first trimester. Polypharmacy, 
defined as taking at least five medications, occurred in 2915 (30.5%) women. Excluding vitamins, 
supplements, and vaccines, 73.4% of women took a medication during pregnancy, with 55.1% 
taking one in the first trimester. The categories of drugs taken in pregnancy and in the first 
trimester include the following: gastrointestinal or antiemetic agents (34.3%, 19.5%), antibiotics 
(25.5%, 12.6%,), and analgesics (23.7%, 15.6%, which includes 3.6%; 1.4% taking an opioid pain 
medication).
Conclusions—In this geographically and ethnically diverse cohort of nulliparous pregnant 
women, medication use was nearly universal and polypharmacy was common.
Introduction
More adults in the U.S. are taking prescription medications over the last two decades.[1] 
Most pregnant women take prescription medications also, with rates as high as 95%.[2–4] In 
addition, in some populations the majority of women have been found to take more than 
three prescription medications during pregnancy.[5, 6] The use of over-the-counter 
medication is likewise increasing in the general population, as are the total dollars spent on 
over-the-counter medicines.[7, 8]
While several reports described prescription and other medication use in pregnancy, they 
have some limitations. Many prior studies reported on single-site cohorts of pregnant 
women, were case-control designs, or utilized larger databases of administrative or 
prescription data.[3, 4, 9–11] A prospectively evaluated study of nulliparous women 
beginning in the first trimester of pregnancy, the nuMoM2b cohort is ideally positioned to 
provide a snapshot of the use of both prescription and non-prescription medications in 
pregnancy. The objective of this study was to characterize medication use in a 
geographically and ethnically diverse cohort of women in their first pregnancy enrolled in 
the nuMoM2b study. A secondary objective was to chronicle trends in medication use over 
the course of pregnancy.
Materials and Methods
The nuMoM2b study was designed as a prospective, longitudinal cohort study whose aim 
was to determine maternal characteristics, including genetic, physiologic, and environmental 
factors that predict adverse pregnancy outcomes. A full description of the study methods and 
visits is described elsewhere.[12] Briefly, 10,038 nulliparous women were recruited in the 
first trimester of pregnancy between October 2010 and September 2013. Women had study 
visits between gestational weeks 6+0/7 and 13+6/7 (Study Visit 1), 16+0/7 and 21+6/7 
(Study Visit 2), and between 22+0/7 and 29+6/7 (Study Visit 3). Study visits were not part 
of clinical care. At each study visit, a trained research team member administered several 
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questionnaires and surveys and collected an array of biological samples. The study team also 
captured data and specimens from antepartum and delivery hospitalizations. At least 30 days 
after delivery, certified chart abstractors reviewed antenatal, intrapartum, and postpartum 
medical records to corroborate existing interview data and collect obstetric and infant 
outcome data.[12]
In the nuMoM2b study, women were recruited from 8 geographically diverse clinical centers 
in the United States to obtain a racial-ethnically diverse population of pregnant women. Sites 
were located in New York or Delaware (combined site), Pennsylvania (2), Ohio, Indiana, 
Illinois, Utah, and California. Women were recruited from both private practices and 
academic practices located near the main clinical site. Women could be recruited as young 
as age 13 into the cohort. Local governing IRBs approved the protocol at each clinical site 
and at the Data Coordinating Center and all participants gave written informed consent. The 
study was registered on clinicaltrials.gov (NCT01322529).
At each study visit, a log of medical conditions and prescription and other medication use 
was completed. At the time the study visit was scheduled, participants were encouraged to 
bring in all medications that they had taken since becoming pregnant or since the previous 
study visit, as applicable. At the study visit, participants were also asked to recall other 
medications, including any over-the-counter medications or supplements (including prenatal 
vitamins, micronutrients, herbals, etc.), they had taken or their provider had recommended in 
that same period. At the time of the delivery, women were asked to recall any medications 
taken up to the time of the delivery hospitalization. Research personnel recorded all answers 
on the data capture form, which were kept in the study file and added to or clarified at each 
subsequent study visit. Participants were asked the reason that the medications were taken 
and answers were coded from a list of conditions on the data capture form (Supplemental 
Material). At the time of final chart abstraction, additional prescribed medications that were 
used at any time during the pregnancy were recorded.
Medications were categorized based on typical use or medication classification. This was to 
allow for ease of grouping. An individual taking two different medications for a condition 
would have two different notations made for that medication category and reason. A key was 
provided with common examples of certain types of medications. For example, a number of 
calcium channel blockers (nifedipine, amlodipine, etc.) were listed for inclusion in the 
medication category of “Ca-Channel Blocker” in the Manual of Operations to facilitate data 
collection and abstraction.
Collected data underwent rigorous quality control review by a subset of investigators (DMH, 
DJM, DTD, CBP, AL, and UMR) to eliminate misspellings and miscategorizations. 
Questions about medication categorizations or indications for medication use were resolved 
through consensus discussion. For the purposes of this analysis, we did not include illicit or 
recreational drugs (such as marijuana, heroin, etc.) but included opioid prescription 
medications and medication-assisted treatment with opioids.
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Statistical analysis
We restricted this analysis to nulliparous women followed through pregnancy from the first 
trimester with medication use data forms completed. Descriptive statistics for individual 
medication category (during pregnancy and during the first trimester, including 95% 
confidence intervals) and indications for medication use are presented for both prescription 
and non-prescription medications and supplements taken at any time during the pregnancy. 
We excluded reports of vaccinations received during pregnancy for statistics pertaining to 
general medication use. Trends of medication use throughout the pregnancy and most 
common reasons for taking medications during pregnancy are also presented. Prevalence 
rates of medication use (overall, in the first trimester, and polypharmacy) were compared by 
ethnicity, geographic region, and other demographic characteristics. Polypharmacy was 
defined as use of at least five medications during the same epoch, a threshold commonly 
used in the literature.[1, 13] Trends by demographic characteristics were evaluated using 
chi-square tests. McNemar’s test was used to evaluate differences in proportion of women 
using medications during the first trimester versus the second. There was no adjustment for 
multiple comparisons. Analyses were conducted using SAS version 9.4 (SAS Institute Inc).
Results
Of the 10,038 participants in nuMoM2b, medication data were available for 9,546 women 
followed through pregnancy from the first trimester with medication data. Restricting to 
women who were followed until the end of their pregnancy excluded 444 women. 
Restricting to women with medication data further excluded 48 women. Characteristics of 
this final cohort and comparison of rates of medication use are presented in Table 1. The 
mean age of the cohort was 27.0 (± 5.66) years.
In total, 9,262 (97.0%, 95% Confidence Interval (CI) 96.7%-97.4%) took at least one 
medication during pregnancy, 9,133 (95.7%, 95% CI 95.3%-96.1%) took a medication 
during the first trimester, and 2,195 (30.5%, 95% CI 29.6%-31.5%) met the definition for 
polypharmacy in taking 5 or more medications during pregnancy. The overall mean number 
of total medications taken during pregnancy was 3.74±2.71 (range 0-27; median 3; 
interquartile range [2, 5]). Women in the cohort took a mean of 2.54±1.96 (range 0-21; 
median 2; interquartile range [1, 3]) medications during the 1st trimester. 2,255 (23.6%) 
women only took prenatal vitamins during pregnancy. Additionally, 193 (2.0%) women took 
some type of herbal or probiotic supplement. The mean number of medications taken by 
women was 2.54±1.96 (range 0-21; median 2; interquartile range [1,3]) at the 1st study visit, 
2.50±1.78 (range 0-18; median 2; interquartile range [1,3]) at the 2nd study visit, 2.59±1.93 
(range 0-24; median 2; interquartile range [1,3]) at the 3rd study visit, and 2.71±2.00 (range 
0-26; median 2; interquartile range [1,4]) at the time of delivery.
Excluding prenatal vitamins, multivitamins, additional iron and folic acid, 7,007 (73.4%, 
95% CI 72.5%-74.3%) of women took a medication during pregnancy, with 5,263 (55.1%, 
95% CI 54.1%-56.1%) taking at least one medication in the 1st trimester (Appendix 1, 
available online at http://links.lww.com/xxx). In this group, 1,240 (13.0%, 95% CI 
12.3%-13.7%) of women met the definition of polypharmacy.
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The number of women taking medications anytime during pregnancy varied by maternal 
age, race-ethnicity, educational attainment at the time of pregnancy, method of payment for 
healthcare, and geographic region (Table 1). Women who were younger and non-Hispanic 
reported higher rates of taking medications in pregnancy. The number of women taking 
medications in the first trimester also varied by age, race-ethnicity, method of payment for 
health care, and region. The number of women reporting polypharmacy (≥ 5 medications) 
also varied by age, race-ethnicity, educational attainment, method of paying for health care, 
household income, and region. Women who were older, white, had commercial insurance, 
and more education tended to take more medication. Women in the northeast tended to take 
less medication.
The most commonly prescribed medications were gastrointestinal or anti-emetic agents 
(3,279 [34.3%]; 1,866 [19.5%] in the first trimester), followed by antibiotics (2,439 [25.5%]; 
1,199 [12.6%] in the 1st trimester) and analgesics (2,265 [23.7%]; 1,485 [15.6%] in first 
trimester). Table 2 presents grouped medication code category data recorded. Appendix 2 
(available online at http://links.lww.com/xxx) details all individual medication codes and 
prevalence of use. Regarding gastrointestinal (GI) & anti-emetic agents, 5-HT3 antagonists 
were the most prescribed specific class of medications (1,167 [12.2%] women). The most 
common indication for this class of medication was nausea and vomiting. Penicillin-
derivative antibiotics were the most commonly reported antibiotic group (715, [7.5%]) and 
were most commonly prescribed for urinary tract infection. However, they were not the most 
prevalently prescribed antibiotic group for such infections. Acetaminophen was reportedly 
taken during pregnancy by 1,903 (19.9%) of women, with 1,121 (11.7%) having taken it in 
the first trimester. Otherwise, non-steroidal anti-inflammatory drugs (NSAIDs) were the 
most commonly reported specific class of analgesics (6.6%), with opioids reported by 3.6% 
of women before delivery. Antihistamines (n=1,219 [12.8%]) were also commonly 
prescribed. Additional iron supplements were noted for 1,548 (16.2%) women.
Vitamin consumption early in pregnancy was nearly universal, with 8,800 women taking a 
prenatal vitamin in the first trimester of pregnancy (92.2%) (Table 2). Additionally, 543 
(5.7%) and 1,859 (19.6%) women took another type of multivitamin or other vitamin, 
respectively, during the first trimester. In total, 9001 (94.3 %) women took some type of 
vitamin or additional folic acid during the first trimester of pregnancy.
Excluding medications taken which were marked as being taken for preventive reasons, 
“other” reasons, or from “provider recommendation”, the specific condition most often cited 
as the reason for taking a medication during pregnancy was nausea and vomiting (n= 1,599 
[16.8%]). This was followed by urinary tract infections (1,132 [11.9%]), anemia (924 
[9.7%]), respiratory infections (737 [7.7%]), yeast infections (717 [7.5%]), mental health 
conditions (706 [7.4%]), and asthma (653 [6.8%]). (Table 3)
Table 4 shows the classes of medications that demonstrated significant increase or decrease 
in use between the first trimester and the second trimester (when participants may have 
previously received counseling on appropriate medication use in pregnancy). The number of 
women who had taken NSAIDs, selective serotonin reuptake inhibitors (SSRIs), and 
progesterone (not for contraception) decreased between study visit 1 and 2 (Table 4). The 
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greatest absolute increase in medication class reported occurred for other analgesics 
(category including acetaminophen) and gastrointestinal agents.
Discussion
Our results from a large, diverse, prospective cohort of nulliparous women in the U.S. detail 
that prescription or other medication use is nearly universal during pregnancy. The 
ubiquitous use of at least one medication during pregnancy and especially in the first 
trimester highlights the need for more attention to medication use in pregnancy. Even when 
vitamins, supplements and vaccines are excluded, 73.4% of women took at least one 
medication during pregnancy, with 55.1% taking a medication in the first trimester, a critical 
time in fetal development. Our findings support the need for more information on 
medications specific to pregnant women and counseling to limit exposure to medically 
unindicated medications in pregnancy.[14–17]
Our findings are consistent with other studies showing that >90% of women take at least one 
medication during pregnancy.[3–6] However, we noted a similar or higher rate of non-
vitamin or supplement medication use than in other studies.[3, 4] This observation may have 
been because of our prospective, study visit interview-based methodology where all 
participants were encouraged to bring in all medications and supplements they were taking. 
Glover et al. utilized interviews but studied a relatively small rural population of 578 women 
and found that only 59.7% of women used a prescription medication excluding vitamins and 
iron supplements.[4] Our rate also may have been higher because we included prescription 
and non-prescription medications. We sought to obtain a more comprehensive picture of all 
medications being consumed in this national cohort. Glover et al. noted a very high rate of 
over the counter medication use (92.6%).[4] Utilizing a survey of 418 postpartum women, 
Refuerzo et al. found that 76.5% of women took a prescription medication after excluding 
vitamins and iron, a rate similar to ours.
Our finding of medications for nausea and vomiting being the most commonly utilized is not 
surprising given the high incidence of nausea and vomiting of pregnancy (NVP).[18] 
Interestingly, we found that 5-HT3 antagonists were the most commonly used medication for 
this indication. Current recommendations do not support these medications as first line 
therapy for NVP.[18–20] In this way, these data can help shed light on current practice 
patterns in relationship to practice recommendations, highlighting areas of need for provider 
education. Taken as a whole medication class category, the high rate of use of GI 
medications (34.3%) is understandable as they treat common conditions such as NVP, acid 
reflux, and constipation. Our finding that anti-infective medications and analgesic 
medications were the next most commonly used medication classes is also consistent with 
other studies, nearly all of which have noted these classes as the three most commonly 
reported.[2, 4, 6, 9–11] Vaginal antifungals, penicillin-derivatives, and nitrofurantoin were 
the most common anti-infective medication classes utilized by women in our cohort. This 
finding is also consistent with other studies. Interestingly, other cohorts noted higher rates of 
antibiotic use, with Palmsten et al. reporting almost 50% of women filling prescriptions for 
such anti-infective agents, with nitrofurantoin at 21.6% of women and metronidazole at 
19.4% of women.[11] We also found relatively high rates of pregnant women using URI 
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agents (16.4%), asthma medications (9.1%), and antidepressants (6.1%). Other studies have 
noted increasing rates of use of various classes of medications over time, including these.[5] 
While differing data collection and categorization methodology prevent direct correlation, 
these relatively high rates are consistent with recently published rates from other studies.[3, 
4, 11]
We found a relatively low rate of opioid use in our cohort (3.6%) compared to some other 
reports. This may have been due to our parsing out different types of analgesics 
methodically by reason codes. It also may be because we did not include medications taken 
during or after the delivery hospitalization, when many women are given opioids. With the 
current epidemic of opioid use disorder, it is important to monitor their use in pregnancy.[21] 
Our rate of opioid use in the 1st trimester is consistent with the 1.3% rate of hydrocodone 
use reported by Thorpe et al.[9] Other groups also found that opiates were commonly used 
by pregnant women, with rates from 8% to nearly 12%.[4, 11] These results do not include 
illicit drug use in this class. Rates of illicit drug use have varied but have been found to be as 
high as 13% in some general obstetrical populations.[22] These rates are increasing.[23] Our 
rates of reported NSAID use were higher than anticipated. However, other studies have 
reported rates of over-the-counter ibuprofen use in pregnancy of up to 18%.[10]
We found that medication use during pregnancy and in the first trimester varied by several 
demographic factors, consistent with other national data.[5] The regional difference in 
polypharmacy was interesting, with rates in the Midwest and West double that of the 
Northeast. As there were several centers in each region, this is unlikely to be due to practice 
patterns within individual centers. Other studies have also found regional variation in 
medication use in pregnancy.[2] Additionally, racial-ethnic differences are seen in 
polypharmacy rates. In our cohort, Hispanic and Asian women had a more than 10% lower 
rate of polypharmacy compared to White non-Hispanic women. These findings bear further 
exploration.
Our rate of polypharmacy of 13.0% after exclusion of vitamins and vaccines is consistent 
with the 15% rate found in a national survey of adults.[1] Other studies in pregnancy in 
which polypharmacy was defined as at least 4 medications, reported rates of 13.6-15.7%.[3, 
5] However, vitamins or supplements often were included in this estimate. When including 
these medications in our cohort, the polypharmacy rate was 30.5%.
We did not classify our medication data by the FDA Pregnancy Category System. Since June 
2015, this system has been replaced by the new Pregnancy and Lactation Rule.[24] As such, 
we did not determine rates of women taking medications in various Drug Categories per the 
old A,B,C,D,X system. Other reports consistently showed that pregnant women generally 
consume category D or X drugs with rates up to 4.5%.[2] One study of Medicaid 
prescription data noted that almost 40% of women received a prescription for a Category D 
drug.[11]
Our work is subject to the limitations of the study design. We attempted to enhance 
completeness of the data set by asking women to bring in prescriptions and any other 
medications taken since the prior study visit. Additionally, the study team had tables of 
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common generic and brand name medications for different conditions to aid with recall. All 
study team members were trained in this interview process but we cannot know if all study 
aids were applied uniformly. We also did not separately categorize medications as being over 
the counter or prescription since we were more interested in ascertaining all medications that 
had been taken. This report does not include any medications taken during or after the 
delivery hospitalization. While there was geographic diversity to the clinical sites within 
nuMoM2b, there were no clinical sites in the South, potentially limiting generalizability for 
that region.
The nuMoM2b study comprises a large prospective cohort capturing prescription and over-
the-counter medication intake longitudinally from the first trimester in a robust, interview-
based manner. Thus, these data help to overcome limitations of other reports that were based 
on administrative prescription databases, retrospective questionnaires, and teratology 
databases. As the nuMoM2b cohort was geographically and ethnically diverse, these data 
should be generalizable to much of the U.S. population.
In conclusion, our findings indicate that medication use in pregnancy is ubiquitous and that 
most pregnant women take multiple medications, including during the first trimester. 
Gastrointestinal medications, antibiotics, and analgesics were the most commonly taken 
medication classes. Armed with data from this and other studies, research should focus on 
improving pregnancy-specific knowledge and guidance for prescribers and pregnant women.
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Table 2
Prevalence of Medication Classes Used During Pregnancy
Medication Class Women taking medication Women taking medication during 
pregnancy†
Women taking medication in the first 
trimester of pregnancy†
Analgesics 2470 (25.9) 2265 (23.7) 1485 (15.6)
Antibiotics 2701 (28.3) 2439 (25.5) 1199 (12.6)
Antifungals 814 (8.5) 749 (7.8) 304 (3.2)
Antivirals 461 (4.8) 428 (4.5) 133 (1.4)
Anticoagulants 79 (0.8) 72 (0.8) 49 (0.5)
Antipsychotics 55 (0.6) 44 (0.5) 38 (0.4)
Antidepressants 673 (7.1) 579 (6.1) 502 (5.3)
Anticonvulsants 373 (3.9) 301 (3.2) 238 (2.5)
Tocolytics 151 (1.6) 147 (1.5) 4 (0.0)
Antihypertensives 221 (2.3) 207 (2.2) 124 (1.3)
Diuretics 37 (0.4) 23 (0.2) 16 (0.2)
GI & Anti-emetic agents 3402 (35.6) 3279 (34.3) 1866 (19.5)
Chemotherapeutics 9 (0.1) 4 (0.0) 4 (0.0)
Steroids (systemic) 419 (4.4) 380 (4.0) 103 (1.1)
Hormonal contraceptives 347 (3.6) 90 (0.9) 90 (0.9)
Progesterone 377 (3.9) 319 (3.3) 242 (2.5)
Thyroid Agents 476 (5.0) 454 (4.8) 431 (4.5)
Asthma Medications 941 (9.9) 866 (9.1) 721 (7.6)
URI Agents 1675 (17.5) 1567 (16.4) 889 (9.3)
Other Mental Health Agents 26 (0.3) 22 (0.2) 13 (0.1)
Anti-diabetic medications 337 (3.5) 315 (3.3) 206 (2.2)
Other Medication 1052 (11.0) 797 (8.3) 464 (4.9)
Vitamins 9433 (98.8) 9165 (96.0) 9009 (94.4)
Overall 9479 (99.3) 9272 (97.1) 9139 (95.7)
Data are presented as n (%)
*
Data presented as the count of the number of women who had indicated taking at least one medication in that overall class. GI= gastrointestinal, 
URI= upper respiratory infection
†All women included in taking prescription and other medications in the first trimester also by definition are included in the column as taking 
medications at any time in pregnancy. The “Women taking medication” includes women who took the medication during pregnancy or during the 3 
months before pregnancy.
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Table 3
Counts of reason codes recorded for why a woman was taking a medication*
Reason Code Count
Preventative, other 17858
Other, not elsewhere specified 5275
Provider recommendation 3419
Nausea and vomiting 2202
Urinary tract infection 1406
Respiratory infections, including influenza and other viral infections, bronchitis, etc. 1019
Mental health condition 975
Anemia 967
Asthma 965
Yeast infection 852
Migraine headaches 664
Hypothyroidism 455
Herpes 401
Bacterial vaginosis 357
Diabetes 350
Infertility 336
High blood pressure (hypertension) 258
Preterm contractions / labor 234
Chlamydia 172
Preterm birth prevention 110
Polycystic ovary disease (PCOS) 83
Trichomonas 75
Ulcerative colitis / Crohn’s disease 72
History of blood clots (thrombosis or thromboembolism) or stroke 63
Skin infection (cellulitis) 60
Seizure disorder 58
Kidney disease 54
Other collagen vascular or autoimmune disease 49
Congenital or inherited bleeding disorder, e.g., thrombophilia, hemophilia 30
Gonorrhea 30
Systemic lupus erythematosus (SLE) 27
Rheumatoid arthritis 25
Hyperthyroidism 22
Cholestasis of pregnancy 22
Liver/gall bladder disease 21
Prevention of cerebral palsy 18
Cardiac arrhythmias 16
Cancer/malignancy 14
Sickle cell disease 13
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Reason Code Count
Fibroids 12
Antiphospholipid syndrome (APA) or other acquired thrombophilia 10
Other STD 10
Thrombocytopenia (platelet count too low) 7
Other structural heart disease (heart problem other than valves) 6
HIV/AIDS 6
Trauma 6
Hepatitis B 4
Cervical dysplasia 3
Syphilis 3
Valvular heart disease 2
PROM latency 2
Missing 1
*
Does not prevent a reason code being counted multiple times if accompanying a medication listed multiple times for the same condition but with 
different time codes.
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Table 4
Medications where use differs significantly between first trimester and second
Direction Medication Taking medication before first 
study visit then stopping later 
in pregnancy
Began taking medication 
after first study visit
P Value*
Increase Other Analgesics 70 (0.7) 358 (3.8) <.001
Motility Agents 13 (0.1) 46 (0.5) <.001
Anti-nausea 44 (0.5) 117 (1.2) <.001
5HT3 Antagonist 62 (0.6) 219 (2.3) <.001
H2 Receptor Agonists 17 (0.2) 99 (1.0) <.001
Other GI Agents 65 (0.7) 277 (2.9) <.001
Steroids (Systemic) 23 (0.2) 46 (0.5) 0.006
Decongestants 58 (0.6) 100 (1.0) 0.001
Antihistamines 107 (1.1) 192 (2.0) <.001
Prenatal Multivitamin 84 (0.9) 158 (1.7) <.001
Additional Iron 30 (0.3) 173 (1.8) <.001
Other Vitamin 169 (1.8) 237 (2.5) 0.001
Pertussis 20 (0.2) 38 (0.4) 0.018
Decrease NSAID 330 (3.5) 37 (0.4) <.001
Triptans 36 (0.4) 5 (0.1) <.001
Nitrofurantoin 176 (1.8) 138 (1.4) 0.032
Other Antibiotic 92 (1.0) 51 (0.5) 0.001
SSRI 144 (1.5) 32 (0.3) <.001
NDRI 33 (0.3) 6 (0.1) <.001
GABA Analogs 32 (0.3) 6 (0.1) <.001
Benzodiazepines 88 (0.9) 5 (0.1) <.001
Hormonal Contraceptives 81 (0.8) 0 (0.0) <.001
Progesterone (for Purpose Other than 
Contraception)
141 (1.5) 15 (0.2) <.001
Metformin 58 (0.6) 1 (0.0) <.001
Other Medication 265 (2.8) 63 (0.7) <.001
Other Multivitamin 277 (2.9) 46 (0.5) <.001
Additional Folate 89 (0.9) 47 (0.5) <.001
Influenza (Seasonal/Novel) 787 (8.2) 499 (5.2) <.001
Data are presented as n (%)
*
Medications must have had at least 25 mothers changing their use of the medication between the time periods to be considered. Counts are 
individual participants in the cohort. Comparisons made by McNemar’s Test.
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